WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search

QL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
QL01 ANTINEOPLASTIC AGENTS
QL01X OTHER ANTINEOPLASTIC AGENTS
QL01XC Monoclonal antibodies
QL01XC01 edrecolomab
QL01XC02 rituximab
QL01XC03 trastuzumab
QL01XC05 gemtuzumab ozogamicin
QL01XC06 cetuximab
QL01XC07 bevacizumab
QL01XC08 panitumumab
QL01XC09 catumaxomab
QL01XC10 ofatumumab
QL01XC11 ipilimumab
QL01XC12 brentuximab vedotin
QL01XC13 pertuzumab
QL01XC14 trastuzumab emtansine
QL01XC15 obinutuzumab
QL01XC16 dinutuximab beta
QL01XC17 nivolumab
QL01XC18 pembrolizumab
QL01XC19 blinatumomab
QL01XC21 ramucirumab
QL01XC22 necitumumab
QL01XC23 elotuzumab
QL01XC24 daratumumab
QL01XC25 mogamulizumab
QL01XC26 inotuzumab ozogamicin
QL01XC27 olaratumab
QL01XC28 durvalumab
QL01XC29 bermekimab
QL01XC31 avelumab
QL01XC32 atezolizumab

Last updated: 2019-01-21